VANCOUVER, BC, Aug. 24, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug development company, today announced the appointment of Dr. Konstantin Adamsky of Negev Capital to its Board of Directors, and Jeff Chilton of Nammex to the Company’s Advisory Council. Konstantin Adamsky, PhD, is the Chief Operating…


Previous articleBetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
Next articleMindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder